LR-CHOP-21 regimen: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{SI}} {{CMG}}; {{AE}} {{AV}} | {{SI}} {{CMG}}; {{AE}} {{AV}} | ||
{{SK}}R2CHOP regimen ;Revlimid-Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone Regimen | |||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a chemotherapeutic regimen consisting of [[lenalidomide]], [[rituximab]], [[cyclophosphamide]], [[doxorubicin]], [[vincristine]], and [[prednisolone]]given every 21 days has high activity in relapsed or refractory [[diffuse large B-cell lymphoma]] (DLBCL).<ref name="pmid24831981">{{cite journal| author=Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G et al.| title=Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. | journal=Lancet Oncol | year= 2014 | volume= 15 | issue= 7 | pages= 730-7 | pmid=24831981 | doi=10.1016/S1470-2045(14)70191-3 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24831981 }} </ref> | |||
{{PAGENAME}} refers to a chemotherapeutic regimen consisting of [[lenalidomide|lenalidomide (revlimid)]], [[rituximab]], [[cyclophosphamide]], [[doxorubicin]], [[vincristine]], and [[prednisolone]]given every 21 days has high activity in relapsed or refractory [[diffuse large B-cell lymphoma]] (DLBCL).<ref name="pmid24831981">{{cite journal| author=Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G et al.| title=Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. | journal=Lancet Oncol | year= 2014 | volume= 15 | issue= 7 | pages= 730-7 | pmid=24831981 | doi=10.1016/S1470-2045(14)70191-3 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24831981 }} </ref> | |||
==Regimen== | ==Regimen== | ||
{{chemo|L|Lenalidomide}} | {{chemo|L/R|Lenalidomide (Revlimid)}} | ||
{{chemo|R|Rituximab}} | {{chemo|R|Rituximab}} | ||
Latest revision as of 19:20, 30 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:R2CHOP regimen ;Revlimid-Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone Regimen
Overview
LR-CHOP-21 regimen refers to a chemotherapeutic regimen consisting of lenalidomide (revlimid), rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolonegiven every 21 days has high activity in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[1]
Regimen
L/RLenalidomide (Revlimid)
RRituximab
CCyclophosphamide
HDoxorubicin (Hydroxydoxorubicin Hydrochloride)
OVincristine (Oncovin)
PPrednisolone
Indications
- Relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[1]
References
- ↑ 1.0 1.1 Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G; et al. (2014). "Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial". Lancet Oncol. 15 (7): 730–7. doi:10.1016/S1470-2045(14)70191-3. PMID 24831981.